Effectiveness and safety of intracavernosal incobotulinumtoxina (xeomin®) 100 u as an add-on therapy to standard pharmacological treatment for difficult-to-treat erectile dysfunction: a case series

HIGHLIGHTS

• who: Francois Giuliano and colleagues from the Neuro-Uro-Andrology RPoincare University Hospital, AP-HP, Bvd RPoincare, Garches, France have published the Article: Effectiveness and Safety of Intracavernosal IncobotulinumtoxinA (Xeominu00ae) 100 U as an Add-on Therapy to Standard Pharmacological Treatment for Difficult-to-Treat Erectile Dysfunction: A Case Series, in the Journal: Toxins 2022, 14, x FOR PEER REVIEW of 22/03/2022
• what: The authors aimed to assess the safety and effectiveness of ICI as an add-on therapy to phosphodiesterase-type 5 inhibitors (PDE5-Is) or prostaglandinE1 ICIs (PGE1 ICIs) to treat . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.